These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 33679798)

  • 1. Interaction Between MDSC and NK Cells in Solid and Hematological Malignancies: Impact on HSCT.
    Tumino N; Di Pace AL; Besi F; Quatrini L; Vacca P; Moretta L
    Front Immunol; 2021; 12():638841. PubMed ID: 33679798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphonuclear Myeloid-Derived Suppressor Cells Are Abundant in Peripheral Blood of Cancer Patients and Suppress Natural Killer Cell Anti-Tumor Activity.
    Tumino N; Besi F; Martini S; Di Pace AL; Munari E; Quatrini L; Pelosi A; Fiore PF; Fiscon G; Paci P; Scordamaglia F; Covesnon MG; Bogina G; Mingari MC; Moretta L; Vacca P
    Front Immunol; 2021; 12():803014. PubMed ID: 35116033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human NK cells: From surface receptors to clinical applications.
    Moretta L; Pietra G; Vacca P; Pende D; Moretta F; Bertaina A; Mingari MC; Locatelli F; Moretta A
    Immunol Lett; 2016 Oct; 178():15-9. PubMed ID: 27185471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myeloid Derived Suppressor Cells Interactions With Natural Killer Cells and Pro-angiogenic Activities: Roles in Tumor Progression.
    Bruno A; Mortara L; Baci D; Noonan DM; Albini A
    Front Immunol; 2019; 10():771. PubMed ID: 31057536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human natural killer cells: news in the therapy of solid tumors and high-risk leukemias.
    Pietra G; Vitale C; Pende D; Bertaina A; Moretta F; Falco M; Vacca P; Montaldo E; Cantoni C; Mingari MC; Moretta A; Locatelli F; Moretta L
    Cancer Immunol Immunother; 2016 Apr; 65(4):465-76. PubMed ID: 26289090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural Killer Cell Interactions With Myeloid Derived Suppressor Cells in the Tumor Microenvironment and Implications for Cancer Immunotherapy.
    Zalfa C; Paust S
    Front Immunol; 2021; 12():633205. PubMed ID: 34025641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor promoting capacity of polymorphonuclear myeloid-derived suppressor cells and their neutralization.
    Groth C; Weber R; Lasser S; Özbay FG; Kurzay A; Petrova V; Altevogt P; Utikal J; Umansky V
    Int J Cancer; 2021 Nov; 149(9):1628-1638. PubMed ID: 34224592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models.
    Greene S; Robbins Y; Mydlarz WK; Huynh AP; Schmitt NC; Friedman J; Horn LA; Palena C; Schlom J; Maeda DY; Zebala JA; Clavijo PE; Allen C
    Clin Cancer Res; 2020 Mar; 26(6):1420-1431. PubMed ID: 31848188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myeloid derived suppressor cells in tumor microenvironment: Interaction with innate lymphoid cells.
    Tumino N; Fiore PF; Pelosi A; Moretta L; Vacca P
    Semin Immunol; 2022 Nov; 61-64():101668. PubMed ID: 36370673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression.
    Fleming V; Hu X; Weber R; Nagibin V; Groth C; Altevogt P; Utikal J; Umansky V
    Front Immunol; 2018; 9():398. PubMed ID: 29552012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NK cells and ILCs in tumor immunotherapy.
    Sivori S; Pende D; Quatrini L; Pietra G; Della Chiesa M; Vacca P; Tumino N; Moretta F; Mingari MC; Locatelli F; Moretta L
    Mol Aspects Med; 2021 Aug; 80():100870. PubMed ID: 32800530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloid Cell Modulation by Tumor-Derived Extracellular Vesicles.
    Arkhypov I; Lasser S; Petrova V; Weber R; Groth C; Utikal J; Altevogt P; Umansky V
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32878277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy.
    Gaggero S; Witt K; Carlsten M; Mitra S
    Front Immunol; 2020; 11():621225. PubMed ID: 33584718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy.
    Joshi S; Sharabi A
    Pharmacol Ther; 2022 Jul; 235():108114. PubMed ID: 35122833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing NK Cell-Based Immunotherapy in Myeloid Leukemia: Abrogating an Immunosuppressive Microenvironment.
    Kaweme NM; Zhou F
    Front Immunol; 2021; 12():683381. PubMed ID: 34220833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloid-Derived Suppressor Cells in Tumors: From Mechanisms to Antigen Specificity and Microenvironmental Regulation.
    Yang Y; Li C; Liu T; Dai X; Bazhin AV
    Front Immunol; 2020; 11():1371. PubMed ID: 32793192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasticity of myeloid-derived suppressor cells in cancer.
    Tcyganov E; Mastio J; Chen E; Gabrilovich DI
    Curr Opin Immunol; 2018 Apr; 51():76-82. PubMed ID: 29547768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment.
    Ostrand-Rosenberg S; Fenselau C
    J Immunol; 2018 Jan; 200(2):422-431. PubMed ID: 29311384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. At the Bench: Preclinical rationale for exploiting NK cells and γδ T lymphocytes for the treatment of high-risk leukemias.
    Norell H; Moretta A; Silva-Santos B; Moretta L
    J Leukoc Biol; 2013 Dec; 94(6):1123-39. PubMed ID: 24108703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NK Cells in the Tumor Microenvironment.
    Guillerey C
    Adv Exp Med Biol; 2020; 1273():69-90. PubMed ID: 33119876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.